Eli Lilly and Co. (LLY) said Monday that Taltz, or ixekizumab, met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H study, which evaluated the efficacy and safety of Taltz versus Humira, or adalimumab, in patients with active psoriatic arthritis or PsA who are biologic disease-modifying anti-rheumatic drug (DMARD)-naive.
from RTT - Biotech https://ift.tt/2SQSRC0
via IFTTT
No comments:
Post a Comment